3‐O‐Methyldopa and the response to levodopa in Parkinson's disease
作者： John G. Nutt , William R. Woodward , Stephen T. Gancher , Dawn Merrick
关键词: Metabolite 、 Levodopa 、 Endocrinology 、 Neutral Amino Acids 、 Methyldopa 、 Chemotherapy 、 Parkinson's disease 、 Phenylalanine 、 Internal medicine 、 3-O-Methyldopa 、 Medicine
摘要: Plasma 3-O-methyldopa (3OMD) concentrations in parkinsonian patients treated with levodopa on a long-term basis reflect daily dosage and do not vary markedly during the day. Oral challenges 3OMD reduce clinical response to infusions, but is no more potent than phenylalanine this regard. These observations, plus fact that makes small contribution total concentration of large neutral amino acids competing for transport at blood--brain barrier, support contention an important determinant levodopa.
elsevier.com
sci-hub.se 参考文章(18)
Avinoam Reches, Stanley Fahn, 3-O-methyldopa blocks dopa metabolism in rat corpus striatum. Annals of Neurology. ,vol. 12, pp. 267- 271 ,(1982) , 10.1002/ANA.410120310
Nansie S. Sharpless, Manfred D. Muenter, Gertrude M. Tyce, Charles A. Owen, 3-Methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease Clinica Chimica Acta. ,vol. 37, pp. 359- 369 ,(1972) , 10.1016/0009-8981(72)90456-1
Douglas K Reilly, Leonor Rivera-Calimlim, David Van Dyke, Catechol-O-methyltransferase activity: a determinant of levodopa response. Clinical Pharmacology & Therapeutics. ,vol. 28, pp. 278- 286 ,(1980) , 10.1038/CLPT.1980.161
Lester A. Wade, Robert Katzman, 3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier Life Sciences. ,vol. 17, pp. 131- 136 ,(1975) , 10.1016/0024-3205(75)90248-9
A.L.N. Prasad, Stanley Fahn, A semiautomated method for the rapid determination of dopa: Comparison of plasma and erythrocyte-dopa concentration in levodopa-treated patients Biochemical Medicine. ,vol. 27, pp. 297- 304 ,(1982) , 10.1016/0006-2944(82)90034-5
Cl. Feuerstein, M. Tanche, F. Serre, M. Gavend, J. Pellat, J. Perret, Does O-methyl-dopa play a role in levodopa-induced dyskinesias? Acta Neurologica Scandinavica. ,vol. 56, pp. 79- 82 ,(2009) , 10.1111/J.1600-0404.1977.TB01411.X
G. Curzon, Bharati D. Kantamaneni, June Trigwell, A method for the determination of dopa and 3-O-methyldopa in the plasma of parkinsonian patients Clinica Chimica Acta. ,vol. 37, pp. 335- 341 ,(1972) , 10.1016/0009-8981(72)90453-6
Leonor Rivera-Calimlim, The Clinical Picture and Plasma Levodopa Metabolite Profile of Parkinsonian Nonresponders: Treatment With Levodopa and Decarboxylase Inhibitor JAMA Neurology. ,vol. 34, pp. 228- 232 ,(1977) , 10.1001/ARCHNEUR.1977.00500160042007
J. J. Gervas, V. Muradas, E. Bazan, E. G. Aguado, J. G. de Yebenes, Effects of 3‐OM‐dopa on monoarnine metabolism in rat brain Neurology. ,vol. 33, pp. 278- 278 ,(1983) , 10.1212/WNL.33.3.278
A. Reches, L. R. Mielke, S. Fahn, 3‐O‐Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway Neurology. ,vol. 32, pp. 887- 887 ,(1982) , 10.1212/WNL.32.8.887